Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension
Emma von Witting,Sarah Lindbo,Magnus Lundqvist,Marit Möller,Andreas Wisniewski,Sara Kanje,Johan Rockberg,Hanna Tegel,Mikael Åstrand,Mathias Uhlén,Sophia Hober,Marit Möller,Mathias Uhlén
DOI: https://doi.org/10.1021/acs.molpharmaceut.0c00975
2020-12-01
Molecular Pharmaceutics
Abstract:Albumin-binding fusion partners are frequently used as a means for the in vivo half-life extension of small therapeutic molecules that would normally be cleared very rapidly from circulation. However, in applications where small size is key, fusion to an additional molecule can be disadvantageous. Albumin-derived affinity proteins (ADAPTs) are a new type of scaffold proteins based on one of the albumin-binding domains of streptococcal protein G, with engineered binding specificities against numerous targets. Here, we engineered this scaffold further and showed that this domain, as small as 6 kDa, can harbor two distinct binding surfaces and utilize them to interact with two targets simultaneously. These novel ADAPTs were developed to possess affinity toward both serum albumin as well as another clinically relevant target, thus circumventing the need for an albumin-binding fusion partner. To accomplish this, we designed a phage display library and used it to successfully select for single-domain bispecific binders toward a panel of targets: TNFα, prostate-specific antigen (PSA), C-reactive protein (CRP), renin, angiogenin, myeloid-derived growth factor (MYDGF), and insulin. Apart from successfully identifying bispecific binders for all targets, we also demonstrated the formation of the ternary complex consisting of the ADAPT together with albumin and each of the five targets, TNFα, PSA, angiogenin, MYDGF, and insulin. This simultaneous binding of albumin and other targets presents an opportunity to combine the advantages of small molecules with those of larger ones allowing for lower cost of goods and noninvasive administration routes while still maintaining a sufficient in vivo half-life.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c00975.Sequencing data and experimental data of yield; α-helical structure; monomeric state; and binding of the evaluated protein variants (PDF)This article has not yet been cited by other publications.
pharmacology & pharmacy,medicine, research & experimental